Home

Ausgabe Kampf alias reuters teva Wecken Missbrauch Ameise

A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New  York Times
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times

Teva chief executive Shlomo Yanai speaks during a tour at the company's new  distribution centre in
Teva chief executive Shlomo Yanai speaks during a tour at the company's new distribution centre in

The logo of Croatia's pharmaceutical company Pliva owned by Teva  Pharmaceutical Industries is seen in front of the company's building in  Zagreb March 18, 2010. Pliva was Croatia's biggest drugs firm in the 1990s  and traded on the London Stock ...
The logo of Croatia's pharmaceutical company Pliva owned by Teva Pharmaceutical Industries is seen in front of the company's building in Zagreb March 18, 2010. Pliva was Croatia's biggest drugs firm in the 1990s and traded on the London Stock ...

Teva to proceed with Rimsa breach of contract suit after ruling
Teva to proceed with Rimsa breach of contract suit after ruling

Teva settles shareholder lawsuit over generic drug pricing for $420 mln |  Reuters
Teva settles shareholder lawsuit over generic drug pricing for $420 mln | Reuters

Teva settles shareholder lawsuit over generic drug pricing for $420 mln |  Reuters
Teva settles shareholder lawsuit over generic drug pricing for $420 mln | Reuters

The logo of Croatia's pharmaceutical company Pliva owned by Teva  Pharmaceutical Industries is seen at the top of the company's building in  Zagreb March 18, 2010. Pliva was Croatia's biggest drugs firm
The logo of Croatia's pharmaceutical company Pliva owned by Teva Pharmaceutical Industries is seen at the top of the company's building in Zagreb March 18, 2010. Pliva was Croatia's biggest drugs firm

A Teva Pharmaceutical Industries building is seen in Jerusalem December 14,  2017. REUTERS/Ammar Awad Stock Photo - Alamy
A Teva Pharmaceutical Industries building is seen in Jerusalem December 14, 2017. REUTERS/Ammar Awad Stock Photo - Alamy

Reuters: Teva to pay US government $519 million over foreign bribery  charges - Dec. 22, 2016 | KyivPost | KyivPost - Ukraine's Global Voice
Reuters: Teva to pay US government $519 million over foreign bribery charges - Dec. 22, 2016 | KyivPost | KyivPost - Ukraine's Global Voice

Allergan to sell a quarter of its Teva stake in first quarter of 2018 |  Reuters
Allergan to sell a quarter of its Teva stake in first quarter of 2018 | Reuters

Reuters: U.S. states accuse Teva of price-fixing • Rx|X Consulting
Reuters: U.S. states accuse Teva of price-fixing • Rx|X Consulting

Levinstein's purchase of Teva's Jerusalem plant in doubt - Globes
Levinstein's purchase of Teva's Jerusalem plant in doubt - Globes

Teva buys Anda for $500 million - ISRAEL21c
Teva buys Anda for $500 million - ISRAEL21c

An employee of Teva Pharmaceutical Industries stands in its Jerusalem oral  solid dosage plant (OSD) December 21, 2011. Israel-based Teva is the  world's leading generic drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags:  BUSINESS
An employee of Teva Pharmaceutical Industries stands in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. Israel-based Teva is the world's leading generic drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags: BUSINESS

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports |  Ctech
CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports | Ctech

Teva Pharmaceuticals at heart of major price fixing suit in US -  www.israelhayom.com
Teva Pharmaceuticals at heart of major price fixing suit in US - www.israelhayom.com

Teva tries to clear Allergan deal with $2B more in asset sales: Reuters |  FiercePharma
Teva tries to clear Allergan deal with $2B more in asset sales: Reuters | FiercePharma

California judge rules for Israeli Teva in major opioid lawsuit - The  Jerusalem Post
California judge rules for Israeli Teva in major opioid lawsuit - The Jerusalem Post

GSK's $235 million verdict revived against Teva, again | Reuters
GSK's $235 million verdict revived against Teva, again | Reuters

Shlomo Yanai, Teva's president and chief executive, speaks to the media  during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical  Industries, the world's largest generic drugmaker, reported higher quarterly
Shlomo Yanai, Teva's president and chief executive, speaks to the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly

The logo of Teva Pharmaceutical Industries is seen on a part of their  building in Jerusalem December 14, 2017. REUTERS/Ammar Awad Stock Photo -  Alamy
The logo of Teva Pharmaceutical Industries is seen on a part of their building in Jerusalem December 14, 2017. REUTERS/Ammar Awad Stock Photo - Alamy

An employee of Teva Pharmaceutical Industries walks in its Jerusalem oral  solid dosage plant (OSD) December 21, 2011. Israel-based Teva is the  world's leading generic drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags:  BUSINESS
An employee of Teva Pharmaceutical Industries walks in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. Israel-based Teva is the world's leading generic drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags: BUSINESS

Teva Pharm Expects About 25 Percent of EpiPen Market by Year End
Teva Pharm Expects About 25 Percent of EpiPen Market by Year End

Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is  seen December 21, 2011. Israel-based Teva is the world's leading generic  drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags: BUSINESS DRUGS SOCIETY  Stock Photo -
Teva Pharmaceutical Industries' Jerusalem oral solid dosage plant (OSD) is seen December 21, 2011. Israel-based Teva is the world's leading generic drugmaker. REUTERS/Ronen Zvulun (JERUSALEM - Tags: BUSINESS DRUGS SOCIETY Stock Photo -

AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report By  Reuters
AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report By Reuters

Teva Pharma shares sink as sales forecast disappoints market
Teva Pharma shares sink as sales forecast disappoints market